Page 208 - Read Online

Page 704 Alonso-Peña et al. Cancer Drug Resist 2019;2:680-709 I http://dx.doi.org/10.20517/cdr.2019.006

46. Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor
in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001;78:110-5.
47. Cao L, Duchrow M, Windhovel U, Kujath P, Bruch HP, et al. Expression of MDR1 mRNA and encoding P-glycoprotein in archival
formalin-fixed paraffin-embedded gall bladder cancer tissues. Eur J Cancer 1998;34:1612-7.
48. Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, et al. Drug sensitivity and drug resistance profiles of human intrahepatic
cholangiocarcinoma cell lines. World J Gastroenterol 2005;11:2748-53.
49. Wolf SJ, Bachtiar M, Wang J, Sim TS, Chong SS, et al. An update on ABCB1 pharmacogenetics: insights from a 3D model into the
location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics. Pharmacogenomics
J 2011;11:315-25.
50. Baldissera VD, de Mattos AA, Coral GP, de Araujo FB, Marroni CA, et al. Evaluation of the C3435T polymorphism in the MDR1 gene
in patients with hepatocellular carcinoma. Ann Hepatol 2012;11:899-906.
51. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A "silent" polymorphism in the MDR1
gene changes substrate specificity. Science 2007;315:525-8.
52. Su Z, Liu G, Fang T, Wang Y, Zhang H, et al. Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma
cells to chemotherapy. Am J Transl Res 2016;8:2790-802.
53. Korita PV, Wakai T, Shirai Y, Matsuda Y, Sakata J, et al. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin
in patients with hepatocellular carcinoma. Oncol Rep 2010;23:965-72.
54. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, et al. Expression of the multidrug resistance proteins MRP2 and MRP3 in
human hepatocellular carcinoma. Int J Cancer 2001;94:492-9.
55. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin
resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 2007;31:1465-72.
56. Martinez-Becerra P, Vaquero J, Romero MR, Lozano E, Anadon C, et al. No correlation between the expression of FXR and genes
involved in multidrug resistance phenotype of primary liver tumors. Mol Pharm 2012;9:1693-704.
57. Zhao J, Yu BY, Wang DY, Yang JE. Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma.
World J Gastroenterol 2010;16:6104-10.
58. Wang Z, Wang B, Tang K, Lee EJ, Chong SS, et al. A functional polymorphism within the MRP1 gene locus identified through its
genomic signature of positive selection. Hum Mol Genet 2005;14:2075-87.
59. Wei D, Zhang H, Peng R, Huang C, Bai R. ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib.
Xenobiotica 2017;47:1008-14.
60. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity:
contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007;132:272-81.
61. Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, et al. Functional characterization of ABCC2 promoter polymorphisms and
allele-specific expression. Pharmacogenomics J 2013;13:396-402.
62. Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, et al. Genetic polymorphisms in the multidrug resistance-associated protein 3
(ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004;14:155-64.
63. Edavana VK, Penney RB, Yao-Borengasser A, Starlard-Davenport A, Dhakal IB, et al. Effect of MRP2 and MRP3 Polymorphisms on
Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples. Int J Cancer Res Mol Mech 2015;1.
64. Eclov RJ, Kim MJ, Chhibber A, Smith RP, Ahituv N, Kroetz DL. ABCG2 regulatory single-nucleotide polymorphisms alter in vivo
enhancer activity and expression. Pharmacogenet Genomics 2017;27:454-63.
65. Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c.3972C>T variant of the multidrug resistance-associated
protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion 2009;80:36-9.
66. Li Z, Xing X, Shan F, Li S, Xiao A, et al. ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based
neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients. Oncotarget 2016;7:55449-57.
67. Han ZG, Tao J, Yu TT, Shan L. Effect of GSTP1 and ABCC2 Polymorphisms on Treatment Response in Patients with Advanced
Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy: A Study in a Chinese Uygur Population. Med Sci Monit
2017;23:1999-2006.
68. Werk AN, Bruckmueller H, Haenisch S, Cascorbi I. Genetic variants may play an important role in mRNA-miRNA interaction: evidence
for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379. Pharmacogenet Genomics 2014;24:283-91.
69. Shibayama Y, Nakano K, Maeda H, Taguchi M, Ikeda R, et al. Multidrug resistance protein 2 implicates anticancer drug-resistance to
sorafenib. Biol Pharm Bull 2011;34:433-5.
70. Rau S, Autschbach F, Riedel HD, Konig J, Kulaksiz H, et al. Expression of the multidrug resistance proteins MRP2 and MRP3 in human
cholangiocellular carcinomas. Eur J Clin Invest 2008;38:134-42.
71. Tomonari T, Takeishi S, Taniguchi T, Tanaka T, Tanaka H, et al. MRP3 as a novel resistance factor for sorafenib in hepatocellular
carcinoma. Oncotarget 2016;7:7207-15.
72. Tsukamoto M, Sato S, Satake K, Miyake M, Nakagawa H. Quantitative Evaluation of Drug Resistance Profile of Cells Expressing Wild-
Type or Genetic Polymorphic Variants of the Human ABC Transporter ABCC4. Int J Mol Sci 2017;18.
73. Lal S, Sutiman N, Ooi LL, Wong ZW, Wong NS, et al. Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin
pharmacokinetics in Asian breast cancer patients. Pharmacogenomics J 2017;17:337-43.
74. Krajinovic M, Elbared J, Drouin S, Bertout L, Rezgui A, et al. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin
cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2016;16:530-5.